Does Wegovy Lower Cortisol Levels — and What Does That Mean for You?

You've read that cortisol causes weight gain, so you're wondering whether Wegovy targets it

It's a reasonable leap. Cortisol, the hormone your adrenal glands release in response to stress, does promote fat accumulation when it stays elevated for weeks or months rather than hours. Visceral fat (the kind that sits around the abdomen and is most strongly associated with metabolic risk) is particularly sensitive to prolonged cortisol exposure. So if you've noticed that a stressful period at work coincided with weight that felt impossible to shift, that's not entirely in your head.

Semaglutide, the active ingredient in Wegovy, works by mimicking the GLP-1 gut hormone to reduce appetite, slow gastric emptying, and influence blood-sugar regulation. Those are the pathways the medicine was designed around. Cortisol regulation sits in a different physiological neighbourhood (the hypothalamic-pituitary-adrenal (HPA) axis) and semaglutide was not developed to target it. When you see headlines suggesting GLP-1 medicines affect cortisol, they almost always describe an indirect effect rather than a direct pharmacological action, and our page on how semaglutide relates to cortisol unpacks that distinction in more detail. The NHS medicines page for semaglutide describes how the drug works without mentioning cortisol reduction, which is a reasonable signal about where the evidence currently sits.

A question our prescribers hear most weeks, in various forms, is whether a patient's high cortisol or chronic stress will stop Wegovy from working. The short answer is that stress can make weight management harder for everyone, but it is not a contraindication, and the consultation process is the right place to discuss the full picture.

What losing weight actually does to your cortisol, and why it matters for this question

The more useful way to think about this is to ask what happens to cortisol when someone loses a meaningful amount of body fat. Some observational research suggests that as visceral fat decreases, basal cortisol output tends to follow it downward, but the relationship is bidirectional and influenced by sleep, inflammation, and metabolic health in ways that make simple cause-and-effect claims unreliable.

In clinical trials, Wegovy produced an average body-weight reduction of around 15% over 68 weeks in adults without type 2 diabetes, as reported in the STEP 1 trial published in the New England Journal of Medicine. At that scale of weight loss, multiple hormonal and metabolic markers improve, insulin sensitivity, inflammatory cytokines, blood pressure, and in some people HbA1c. Whether cortisol shifts consistently alongside those markers is less clearly established, and if that question is on your mind, our dedicated page on whether Wegovy lowers cortisol walks through what the current evidence does and does not show.

If you are curious about how semaglutide interacts with other metabolic markers, the page on whether Wegovy lowers blood sugar covers that territory in more detail. The mechanisms there are better characterised and directly licensed.

When high cortisol is the clinical problem, and Wegovy is not the answer

Cushing's syndrome is the medical condition characterised by pathologically elevated cortisol, caused by a tumour or by long-term corticosteroid use. It produces weight gain, particularly in the face, neck, and abdomen, along with a distinctive set of other signs. If a doctor suspects Cushing's syndrome, the investigation and treatment follow a specific endocrinological pathway. Wegovy is not part of that pathway and would not be appropriate as a primary intervention.

This matters for anyone reading general content about cortisol and weight and wondering whether a weight-loss medicine might address an undiagnosed hormonal problem. The responsible answer is: get the hormonal question investigated properly first. A prescriber reviewing your consultation will flag concerns that point towards an underlying condition that needs separate assessment before weight-loss treatment begins.

For context on semaglutide's licensed indications in the UK (and what the clinical evidence does and does not support) the overview page goes into more depth. Separately, if cost is a consideration, the Wegovy pricing page explains what a legitimate private prescription typically involves, and why the full picture matters more than headline figures alone.

Wegovy is a prescription-only medicine. Before treatment starts, a GPhC-registered Independent Prescriber at our pharmacy reviews your consultation personally, on the same day, without the use of automated decision-making. If the cortisol question is clinically relevant to your situation, that's exactly the kind of thing worth raising. Speak to our prescribers via a free consultation to explore whether Wegovy is the right fit.